Enanta Pharmaceuticals, Inc. announced that the United States District Court of Massachusetts issued an adverse ruling on a summary judgment motion filed by Pfizer, Inc. This ruling pertains to Enanta's patent infringement lawsuit.
The lawsuit seeks damages for infringement of U.S. Patent No. 11,358,953, which is related to Pfizer's COVID-19 antiviral, Paxlovid. Enanta Pharmaceuticals stated its intention to appeal this adverse ruling.
This legal setback represents a challenge to Enanta's intellectual property claims and could impact the potential value derived from its COVID-19 antiviral technology. The appeal process introduces further uncertainty regarding the ultimate outcome of the litigation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.